A One-Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults
Imunologia e AlergiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Allergy
- Publicado em
- 23 fev 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A One-Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults
Marek Jutel, Ludger Klimek, Michael Gerstlauer, Dana Troyke, Kristina Duwensee, C Vogelberg
Descritores MeSH
- Allergens
- Pollen
- Rhinitis, Allergic, Seasonal
- Betula
- Desensitization, Immunologic
- Female
- Humans
- Immunoglobulin E
- Injections, Subcutaneous
- Male
Veja também
Estudos relacionados
- Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG1 Instead of IgG4
- Comparative Efficacy of Subcutaneous and Sublingual Allergen Immunotherapy for Grass Pollen-Induced Allergic Rhinoconjunctivitis: Pairwise and Adjusted Indirect Treatment Comparison of Standardized ALK Products
- Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy
- Grass pollen allergoids conjugated with mannan for subcutaneous and sublingual immunotherapy: a dose-finding study